The following represents disclosure information provided by authors of this abstract. The ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer Planning Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Discovery of a biomarker signature that predicts upgrading or upstaging in patients with low-risk prostate cancer.
Nicholas Erho
Employment or Leadership Position - GenomeDx Biosciences
Ismael A. Vergara
Employment or Leadership Position - GenomeDx Biosciences
Christine Buerki
Employment or Leadership Position - GenomeDx Biosciences
Mercedeh Ghadessi
Employment or Leadership Position - GenomeDx Biosciences
Anamaria Crisan
Employment or Leadership Position - GenomeDx Biosciences
Thomas Sierocinski
Employment or Leadership Position - GenomeDx Biosciences
Zaid Haddad
Employment or Leadership Position - GenomeDx Biosciences
Benedikt Zimmermann
Employment or Leadership Position - GenomeDx Biosciences
Sebastian Harko
Employment or Leadership Position - GenomeDx Biosciences
Worlanyo Sosu-Sedzorme
Employment or Leadership Position - GenomeDx Biosciences
Timothy J. Triche
Employment or Leadership Position - GenomeDx Biosciences
Consultant or Advisory Role - GenomeDx Biosciences
Stock Ownership - GenomeDx Biosciences
Elai Davicioni
Employment or Leadership Position - GenomeDx Biosciences
Stock Ownership - GenomeDx Biosciences